LIVE NEWS
  • Ledger, BBC Among 178 Organizations Hit by Crypto Malware
  • US basketball player arrested in Nigeria over 75 pounds of cannabis
  • CMS proposes more aggressive audits of Medicare Advantage| STAT
  • Microsoft says months-old bug caused global Microsoft 365 outage
  • James Bond live updates: Robert Pattinson named as new 007
  • Wildfire Lawsuits Against Utilities Fuel a Debate Over Who Should Pay
  • Tiny robots can tumble through blood vessels to help dissolve blood clots, early test shows
  • The Verge’s guide to the best gifts under $100
Prime Reports
  • Home
  • Popular Now
  • Crypto
  • Cybersecurity
  • Economy
  • Geopolitics
  • Global Markets
  • Politics
  • See More
    • Artificial Intelligence
    • Climate Risks
    • Defense
    • Healthcare Innovation
    • Science
    • Technology
    • World
Prime Reports
  • Home
  • Popular Now
  • Crypto
  • Cybersecurity
  • Economy
  • Geopolitics
  • Global Markets
  • Politics
  • Artificial Intelligence
  • Climate Risks
  • Defense
  • Healthcare Innovation
  • Science
  • Technology
  • World
Home»Healthcare Innovation»Talks on launch of clinical trial of Ebola vaccine in DRC advance, WHO says 
Healthcare Innovation

Talks on launch of clinical trial of Ebola vaccine in DRC advance, WHO says 

primereportsBy primereportsAugust 13, 2026Updated:November 2, 2026No Comments5 Mins Read
Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
Talks on launch of clinical trial of Ebola vaccine in DRC advance, WHO says 
Share
Facebook Twitter LinkedIn Pinterest Email


Talks are underway between authorities in the Democratic Republic of the Congo and the World Health Organization to expedite the start of a multi-armed Phase 3 clinical trial of vaccines geared toward helping to contain the spread of the Bundibugyo virus in the northeast of the country, which the director-general of the global health agency warned Wednesday is on track to become the largest Ebola outbreak on record.

“It’s already the second-biggest Ebola epidemic on record, and it’s moving faster than any previous Ebola outbreak. At its current pace, it’s on track to eclipse the West African Ebola outbreak of 2014-2016,” Tedros Adhanom Ghebreyesus said during a news conference in Geneva. 

The first vaccine to be pushed into the field for study will be Merck’s Ervebo, a vaccine that targets a different species of the virus, Ebola Zaire. An expert panel that advises the WHO was initially reluctant to recommend its use, but an increasing number of studies in animals and in people have persuaded it that the vaccine could offer some cross-protection against Bundibugyo, and should be tested to see if it could help. 

“WHO has recommended inclusion of the vaccine in a Phase 3 trial, which we hope to start as soon as possible,” Tedros said. “We do not know whether this vaccine is efficacious against Bundibugyo disease in humans. The Phase 3 trial is the best way to ensure a safe and effective vaccine is available as soon as possible for this and future outbreaks.”

As of Monday, more than 4,500 cases of Ebola have been confirmed in this outbreak, centered in the DRC’s Ituri province, near the borders of Uganda and South Sudan. More than 2,060 of those cases have died. 

We prepared for Ebola — but not this Ebola

Vasee Moorthy, head of the WHO’s R&D blueprint program, said the agency is on the verge of submitting a trial protocol to regulatory and ethics committee officials in the DRC to seek their approval. If greenlit, the study would see known contacts of cases randomized to receive Ervebo or a placebo. As other vaccines — specifically ones that directly target the Bundibugyo species of Ebola — become available, they too would be added to the trial.

The trial is not using the ring vaccination approach employed in the Ebola Ça Suffit trial — French for “Ebola, that’s enough” — that proved Ervebo’s effectiveness and was conducted in Guinea during the West African outbreak. In that trial, rings of contacts of cases, as well as contacts of the contacts, were randomized to either get the vaccine immediately or on a delayed basis. Field studies have later estimated Ervebo’s effectiveness against Ebola Zaire at about 84%. 

Moorthy said the results of multiple Ebola trials conducted in the intervening years led officials to conclude that randomizing contacts individually, rather than as part of a ring of contacts of an infected person, would be a better approach. “It is more efficient to individually randomize,” he said.

The WHO officials did not address — nor were they asked to address — a report this week in which DRC authorities announced they want to roll out Ervebo for general use outside of a clinical trial. The approach has received the support of the Africa Centres for Disease Control and Prevention. 

It is unclear whether the DRC could access the number of vaccine doses that would be needed to put such a plan into action. There is a roughly 500,000-dose stockpile of Ervebo, but it is controlled by the International Coordinating Group on Vaccine Provision, which is run by the International Federation of Red Cross and Red Crescent Societies, Doctors Without Borders (MSF), the United Nations Children’s Fund (UNICEF), and the WHO. STAT asked the WHO about the idea after the press conference but had not yet received a response when this report was published.

Several Bundibugyo-specific vaccines could join the trial in the early autumn, Moorthy suggested. The Oxford Vaccine Group at the University of Oxford is currently conducting a Phase 1 trial of its experimental vaccine, with production partner the Serum Institute of India racing to produce large quantities of doses. And Moderna has begun a Phase 1 trial of a messenger RNA vaccine in Canada. 

Both groups expect to have results of these trials — which provide initial safety and dosing data — in September, Moorthy said, and could be added to the Phase 3 trial if the Phase 1 data support their use.

Though both groups are hoping these vaccines can be used in a single dose, it remains to be seen if they can be effective without a booster. Ervebo is a one-dose vaccine.

A third Bundibugyo-specific vaccine is being developed by the nonprofit group IAVI; it uses the same platform as Ervebo. But it will be several months before enough doses of the vaccine are available for use in a Phase 3 trial.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Previous ArticlePixel 11 event live blog: Let’s watch Trevor Noah introduce Google’s new phones
Next Article Ocean temperatures set to break all-time record: what’s next?
primereports
  • Website

Related Posts

Healthcare Innovation

CMS proposes more aggressive audits of Medicare Advantage| STAT

November 17, 2026
Healthcare Innovation

New company Tom Health aims to fix primary care with AI tool| STAT

November 16, 2026
Healthcare Innovation

HHS, Eli Lilly, Oura, basal ganglia: Readout Newsletter

November 16, 2026
Add A Comment
Leave A Reply Cancel Reply

Top Posts

Threat of further violence looms after Mexican cartel rampage

February 25, 2026116 Views

‘Two-sided risk’ Medicare Advantage plans improve patient outcomes

February 24, 202673 Views

Police chief urges those ‘who know nothing about Northern Ireland’ not to stir up disorder via social media – UK politics live | Politics

June 9, 202631 Views
Stay In Touch
  • Facebook
  • YouTube
  • TikTok
  • WhatsApp
  • Twitter
  • Instagram
Latest Reviews

Subscribe to Updates

Get the latest tech news from FooBar about tech, design and biz.

PrimeReports.org
Independent global news, analysis & insights.

PrimeReports.org brings you in-depth coverage of geopolitics, markets, technology and risk – with context that helps you understand what really matters.

Editorially independent · Opinions are those of the authors and not investment advice.
Facebook X (Twitter) LinkedIn YouTube
Key Sections
  • World
  • Crypto
  • Cybersecurity
  • Geopolitics
  • Global Markets
  • Artificial Intelligence
All Categories
  • Artificial Intelligence
  • Climate Risks
  • Crypto
  • Cybersecurity
  • Defense
  • Economy
  • Geopolitics
  • Global Markets
  • Healthcare Innovation
  • Politics
  • Popular Now
  • Science
  • Technology
  • World
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Cookie Policy
  • DMCA / Copyright Notice
  • Editorial Policy

Sign up for Prime Reports Briefing – essential stories and analysis in your inbox.

By subscribing you agree to our Privacy Policy. You can opt out anytime.
Latest Stories
  • Ledger, BBC Among 178 Organizations Hit by Crypto Malware
  • US basketball player arrested in Nigeria over 75 pounds of cannabis
  • CMS proposes more aggressive audits of Medicare Advantage| STAT
© 2026 PrimeReports.org. All rights reserved.
Privacy Terms Contact

Type above and press Enter to search. Press Esc to cancel.